Skip to main content

Table 4 Demographic characteristic of HCC patients with BCLC 0 and A stage

From: Anatomical sites (Takasaki’s segmentation) predicts the recurrence-free survival of hepatocellular carcinoma

Variables Hepatectomy (n = 126) LT (n = 53) P-value
Age (years) 49.9 ± 11.1 49.9 ± 11.2 0.892
Gender, M/F 121 (96.0%)/5 (4.0%) 50 (98.4%)/3 (1.6%) 0.671
AFP (ng/ml), ≤ 400/ > 400 82 (65.1%)/34 (34.9%) 42 (79.2%)/11 (20.8%) 0.243
HBV-DNA, ±  88 (69.8%)/38 (30.1%) 26 (49.1%)/27 (50.9%) 0.008
Prothrombin time (s) 13.6 ± 1.2 14.6 ± 3.2 0.001
FIB-4 2.5 ± 1.9 2.7 ± 1.5 0.464
Tumor size (cm), < 5/ ≥ 5 76 (60.3%)/50 (49.7%) 28 (52.8%)/25 (47.2%) 0.354
Tumor nodule number, Single / Multiple (≥ 2) 122 (96.8%)/4 (3.2%) 50 (94.4%)/3 (5.6%) 0.433
MVI, ±  14 (11.1%)/112 (88.9%) 16 (30.2%)/37 (69.8%) 0.002
Differentiation gradea, I–II/III–IV 118 (93.7%)/8 (6.3%) 47 (88.7%)/6 (11.3%) 0.258
BCLC stage, 0/A 20 (15.9%)/106 (84.1%) 12 (22.6%)/41 (77.4%) 0.281
  1. HCC hepatocellular carcinoma, BCLC Barcelona Clinic Liver Cancer, LT liver transplantation, AFP alpha-fetoprotein, MVI microvascular invasion, HCC hepatocellular carcinoma
  2. aEdmondson-Steiner grade